Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Test Beds, Digital Hubs And Innovation Tariffs Top Medtech News At UK's NHS Expo

Executive Summary

The annual NHS Health & Care Innovation Expo struck positive notes for medtech and digital, and just for a change, the UK's health-care leaders could bask in the glow of an appreciative audience.

You may also be interested in...



Into 2019: Intelligent Innovation's Role In The Shape Of Medtech Things To Come

Brexit, the "Implant Files" and the new EU regulations – however large they loom at present, they will in time be seen as mere tactical challenges for a global medtech industry working hard to ensure that it is ready for the massive health-care delivery and service-oriented changes to come. Preparing for the future and maximizing current market penetration – in the UK, the EU and beyond – were key themes at UK HealthTech 2018, held in Cardiff, Wales.

UK Innovation, EU Regulation And Digital Transformation Are Top Themes For Medtechs At NHS Expo 2018

NHS England chief Simon Stevens has a habit of stealing headlines in UK health-care circles, and his CAR-T cell therapy approval announcement did the trick at the NHS 2018 Innovation Expo. But medtech innovation schemes and furthering the UK digital agenda emerged as main talking points at the meeting.

How The EHR And New Data Streams Are Influencing Clinical Practice

A plethora of clinical studies are showing that new types of data, often captured in the EHR, can help improve the correlation between treatments and outcomes and favorably affect patient care as well as enhance drug development.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT121495

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel